| Fiedler, Walter |
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics |
|
|
| Recruiting | 3 | 882 | Europe | Cytarabine, Daunorubicin, CPX-351 | University of Ulm, Jazz Pharmaceuticals | Acute Myeloid Leukemia | 06/27 | 06/27 | | |
NCT04628026: Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2 |
|
|
| Recruiting | 3 | 650 | Europe | Venetoclax, Placebo, Standard chemotherapy, Autologous stem cell transplantation, Allogeneic stem cell transplantation | University of Ulm, Stichting Hemato-Oncologie voor Volwassenen Nederland | Acute Myeloid Leukemia, Myelodysplastic Syndromes | 02/25 | 02/31 | | |
| Completed | 2 | 52 | Europe | Blinatumomab, blincyto | Goethe University | B-Precursor ALL | 01/24 | 01/24 | | |
NCT06648889: Isatuximab in Adult Patients with Cytologic or Molecular Relapsed/refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia |
|
|
| Recruiting | 2 | 40 | Europe | Isatuximab, Bortezomib | Goethe University, Sanofi | T-ALL | 02/28 | 08/28 | | |
GMALL-BLIVEN, NCT05182385: Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) |
|
|
| Recruiting | 1/2 | 39 | Europe | Blinatumomab, blincyto, Venetoclax, Venclyxto | Goethe University, University Hospital Schleswig-Holstein | ALL, Recurrent, Adult | 06/25 | 12/25 | | |
| Recruiting | 1/2 | 413 | Europe, Canada, US, RoW | revumenib, SNDX-5613, cobicistat | Syndax Pharmaceuticals, Syndax Pharmaceuticals, Inc | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage | 12/27 | 12/27 | | |
|
|
|
|
|
|
|
|
|
| Recruiting | 1 | 94 | Europe | IL12-L19L19, Dodekin | Philogen S.p.A. | Advanced Solid Tumor, Metastatic Solid Tumor | 12/25 | 12/25 | | |
NCT04230265: Dose-escalating Trial With UniCAR02-T Cells and CD123 Target Module (TM123) in Patients With Hematologic and Lymphatic Malignancies |
|
|
| Recruiting | 1 | 90 | Europe | Cyclophosphamide (Non-IMP), Fludarabine (Non-IMP), TM123 (IMP), UniCAR02-T (IMP) | AvenCell Europe GmbH, PHARMALOG Institut für klinische Forschung GmbH | Acute Myeloid Leukemia (AML) | 05/25 | 09/25 | | |
AMLSG BiO, NCT01252485: Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - the Biology and Outcome (BiO)-Project |
|
|
| Recruiting | N/A | 50000 | Europe | | University of Ulm | Acute Myeloid Leukemia (AML), MDS/AML | 12/44 | 12/44 | | |
| Balabanov, Stefan |
| Completed | 2 | 72 | Europe | Rituximab, Methotrexate, Procarbazine, Lenalidomide, Radiotherapy, Temozolomide | International Extranodal Lymphoma Study Group (IELSG) | Primary Central Nervous System Lymphoma | 12/24 | 12/24 | | |
